Gritstone Description

The foundational aspect of our immunotherapy approach lies in our comprehension of antigens and neoantigens, particularly in identifying which variations will be transcribed, translated, processed, and subsequently displayed on the surface of cells via Human leukocyte antigen (HLA) molecules, thus making them recognizable to T cells. We achieve this by employing Gritstone EDGETM, a unique platform powered by machine learning. Creating cancer immunotherapies that incorporate tumor-specific neoantigens proves challenging, mainly because tumors consist of numerous mutations, yet only a fraction of these lead to genuine tumor-specific neoantigens. To tackle this complexity, we have developed EDGE's cutting-edge integrated neural network model, trained with millions of data points gathered from a diverse range of tumor and normal tissue samples across various patient ancestries. This extensive training allows us to enhance the accuracy of neoantigen identification and improve the effectiveness of our immunotherapy strategies.

Integrations

No Integrations at this time

Reviews

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Company Details

Company:
Gritstone bio
Year Founded:
2015
Headquarters:
United States
Website:
gritstonebio.com/scientific-platform/

Media

Gritstone Screenshot 1
Recommended Products
AI-powered service management for IT and enterprise teams Icon
AI-powered service management for IT and enterprise teams

Enterprise-grade ITSM, for every business

Give your IT, operations, and business teams the ability to deliver exceptional services—without the complexity. Maximize operational efficiency with refreshingly simple, AI-powered Freshservice.
Try it Free

Product Details

Platforms
Web-Based
Customer Support
Online Support

Gritstone Features and Options

Gritstone User Reviews

Write a Review
  • Previous
  • Next